Brief: Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease
03/04/2025 13:13
April 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025 ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025 ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS Source text: ID:nBw4Hk80Pa Further company coverage: ALDX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug